ライフサイエンスコーパス: rheumatic heart disease

1 including cardiac surgery for congenital and rheumatic heart disease.

2 sorders, including schistosomiasis, HIV, and rheumatic heart disease.

3 nd its peptides appear during progression of rheumatic heart disease.

4 ad prosthetic valve endocarditis, and 5% had rheumatic heart disease.

5 c myosin is important in the pathogenesis of rheumatic heart disease.

6 e postinfection sequelae rheumatic fever and rheumatic heart disease.

7 have been implicated in the pathogenesis of rheumatic heart disease.

8 tissues, and subsequent rheumatic fever and rheumatic heart disease.

9 be an important event in the development of rheumatic heart disease.

10 t myosin are associated with myocarditis and rheumatic heart disease.

11 nts (38%; 15 with bicuspid valves); probable rheumatic heart disease, 8 patients (6%); and miscellane

12 Rheumatic heart disease according to the World Heart Fed

13 Rheumatic heart disease affects 1 in 100 schoolchildren

14 rval, 29.7 million to 43.1 million) cases of rheumatic heart disease and 10.5 million (95% uncertaint

15 re is no vaccine to prevent diseases such as rheumatic heart disease and invasive streptococcal infec

16 ive autoantibodies which target the valve in rheumatic heart disease and the neuronal cell in Sydenha

17 countries, including the cardiac effects of rheumatic heart disease and the vascular effects of mala

18 se, nonischemic and Chagas cardiomyopathies, rheumatic heart disease, and congenital heart anomalies,

19 ion, aortic and peripheral arterial disease, rheumatic heart disease, and endocarditis.

20 Patients with rheumatic heart disease, annular calcification or endoca

21 iomyopathy, atrial fibrillation and flutter, rheumatic heart disease, aortic aneurysm, peripheral art

22 he molecular basis of ARF and the subsequent rheumatic heart disease are poorly understood.

23 Acute rheumatic fever (ARF) and subsequent rheumatic heart disease are rare but serious sequelae of

24 arly detection and the treatment of clinical rheumatic heart disease are required to improve outcomes

25 ds in the prevalence of and mortality due to rheumatic heart disease as part of the 2015 Global Burde

26 ey had a history of a myocardial infarction, rheumatic heart disease, cardiomyopathy, significant val

27 To clarify immune-mediated mechanisms in rheumatic heart disease caused by group A streptococcal

28 and all valvular (n=2504) disease deaths and rheumatic heart disease deaths (n=4713) were studied.

29 Global age-standardized mortality due to rheumatic heart disease decreased by 47.8% (95% uncertai

30 atically reviewed data on fatal and nonfatal rheumatic heart disease for the period from 1990 through

31 ort the 2-year follow-up of individuals with rheumatic heart disease from 14 low- and middle-income c

32 llion) disability-adjusted life-years due to rheumatic heart disease globally.

33 Although rheumatic heart disease has been nearly eradicated in hi

34 The health-related burden of rheumatic heart disease has declined worldwide, but high

35 Patients with clinical rheumatic heart disease have high mortality and morbidit

36 an monoclonal antibodies (mAbs) derived from rheumatic heart disease have provided evidence for cross

37 interval, 297,300 to 337,300) deaths due to rheumatic heart disease in 2015.

38 mary prevention of acute rheumatic fever and rheumatic heart disease in children presenting with phar

39 Evidence suggested that the pathogenesis of rheumatic heart disease involved the activation of surfa

40 Rheumatic heart disease is an autoimmune sequela of grou

41 Rheumatic heart disease is the most common cause of valv

42 art disease were older than children without rheumatic heart disease (median age [interquartile range

43 e current management strategies for valvular rheumatic heart disease on the basis of either strong ev

44 pared with other primary presentations) were rheumatic heart disease or congestive cardiac failure, c

45 the mortality and morbidity associated with rheumatic heart disease or information on their predicto

46 surface antigens may lead to valve damage in rheumatic heart disease or neuropsychiatric behaviors an

47 dividuals with a personal history of chronic rheumatic heart disease (OR = 0.55; 0.33-0.93), particul

48 l disease prevalence of and mortality due to rheumatic heart disease over a 25-year period.

49 Despite the dramatic decline of rheumatic heart disease over the past 5 decades, there h

50 ally associated with intravenous drug abuse, rheumatic heart disease, prosthetic heart valves, pacema

51 increased occurrence of CLL and how chronic rheumatic heart disease protects against CLL, perhaps re

52 Acute rheumatic fever and rheumatic heart disease remain major global health probl

53 Acute rheumatic fever and subsequent rheumatic heart disease remain significant in developing

54 Rheumatic heart disease remains an important preventable

55 e of acute rheumatic fever in North America, rheumatic heart disease remains an infrequent cause of v

56 The study of human T cell clones from rheumatic heart disease revealed potential sites of T ce

57 Rheumatic heart disease (RHD) after group A streptococcu

58 people with acute rheumatic fever (ARF) and rheumatic heart disease (RHD) and the effect of comorbid

59 Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are autoimmune sequelae of

60 Rheumatic heart disease (RHD) is a leading cause of prem

61 Echocardiographic screening for rheumatic heart disease (RHD) is becoming more widesprea

62 s in reported HLA class II associations with rheumatic heart disease (RHD) may have been due to inacc

63 Rheumatic heart disease (RHD) remains a major public hea

64 High-risk patients with rheumatic heart disease (RHD) who were undergoing valve

65 acute rheumatic fever (ARF) and its sequel, rheumatic heart disease (RHD), continue to cause a large

66 he South Pacific experience a high burden of rheumatic heart disease (RHD).

67 ntially powerful tool for early diagnosis of rheumatic heart disease (RHD).

68 hest prevalence rates of clinically detected rheumatic heart disease (RHD).

69 Rheumatic heart disease seems in many ways emblematic of

70 one transitions in developed countries, from rheumatic heart disease to a degenerative calcific patho

71 predominantly communicable diseases such as rheumatic heart disease, tuberculous pericarditis, or ca

72 The prevalence of borderline or definite rheumatic heart disease was 10.2 (95% CI, 7.5-13.0) per

73 e various repair techniques, perhaps because rheumatic heart disease was less common, and the initial

74 ndardized mortality due to and prevalence of rheumatic heart disease were observed in Oceania, South

75 Children with rheumatic heart disease were older than children without